Atlas Trials

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

Clinical trial NCT00703664 · COMPLETED

Trial details

NCT number
NCT00703664
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Mantle Cell LymphomaRecurrent Non-Hodgkin Lymphoma
Start date
2008-07-09
Primary completion
2017-12-01
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.